Abstract #0590

19F-MRI of inhaled perfluoropropane in patients with asthma and patients with COPD pre- and post-bronchodilator therapy

Mary A. Neal¹, Benjamin J. Pippard^1,2, Ian Forrest³, Rod A. Lawson⁴, Holly F. Fisher⁵, John N. S. Matthews⁵, Kieren G. Hollingsworth^1,2, A. John Simpson¹, Jim M. Wild⁶, and Peter E. Thelwall^1,2

¹Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom, ²Newcastle Magnetic Resonance Centre, Newcastle University, Newcastle upon Tyne, United Kingdom, ³Respiratory Medicine, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ⁴Respiratory Medicine, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom, ⁵Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, United Kingdom, ⁶POLARIS, Department of IICD, University of Sheffield, Sheffield, United Kingdom

¹⁹F-MRI of inhaled perfluoropropane can be used for assessment of pulmonary ventilation. Static breath hold ¹⁹F-MR images were acquired pre- and post-bronchodilator following inhalation of a perfluoropropane/oxygen gas mixture in patients with asthma and patients with chronic obstructive pulmonary disease (COPD). Percentage ventilated lung volume (%VV) was calculated from each of the ¹⁹F-MR images. %VV was significantly reduced in both patient groups, and between pre- and post-bronchodilator acquisitions in the asthmatic patient group. A strong positive correlation between %VV and spirometric indices was revealed. Gas inhalations were well tolerated by all participants, with no adverse events.

This abstract and the presentation materials are available to members only; a login is required.

Join Here